TD Cowen Lowers Charles River Laboratories International (NYSE:CRL) Price Target to $228.00

Charles River Laboratories International (NYSE:CRL - Get Free Report) had its price target cut by research analysts at TD Cowen from $260.00 to $228.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a "hold" rating on the medical research company's stock. TD Cowen's target price points to a potential downside of 0.18% from the stock's previous close.

A number of other analysts also recently commented on CRL. Guggenheim downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. Citigroup upped their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. Evercore ISI lifted their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of "Moderate Buy" and a consensus price target of $255.27.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $0.29 during trading on Monday, reaching $228.41. The stock had a trading volume of 447,273 shares, compared to its average volume of 551,078. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The stock has a market cap of $11.77 billion, a PE ratio of 26.71, a PEG ratio of 1.79 and a beta of 1.44. The business has a fifty day moving average price of $249.97 and a 200-day moving average price of $226.26.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts' consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. On average, equities analysts forecast that Charles River Laboratories International will post 11.01 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares of the company's stock, valued at $5,685,431.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently bought and sold shares of the company. VisionPoint Advisory Group LLC raised its holdings in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $37,000. Operose Advisors LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $42,000. Venturi Wealth Management LLC boosted its stake in shares of Charles River Laboratories International by 74.7% in the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after buying an additional 112 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in Charles River Laboratories International by 76.0% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company's stock worth $52,000 after acquiring an additional 95 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).